Articles published by 4M Therapeutics Inc.

4M Therapeutics Announces Appointment of Industry Veteran Edward Scolnick, M.D., as Senior Scientific Advisor

September 25, 2025

From 4M Therapeutics Inc.

Via Business Wire

4M Therapeutics Reports Positive Results from 4MT2001 GLP Safety Studies

June 11, 2025

From 4M Therapeutics Inc.

Via Business Wire

4M Therapeutics to Present at the Upcoming American Psychological Association and American Society of Clinical Psychopharmacology Annual Meetings

April 21, 2025

From 4M Therapeutics Inc.

Via Business Wire

4M Therapeutics Awarded $120,000 Grant from SynGAP Research Fund to Evaluate GSK3β Inhibition in Preclinical SYNGAP1-Related Disorders Research

November 12, 2024

From 4M Therapeutics Inc.

Via Business Wire

4M Therapeutics’ Compounds to Be Utilized in Research Project Funded by National Institute on Aging

October 17, 2024

From 4M Therapeutics Inc.

Via Business Wire

4M Therapeutics Announces Positive Preclinical Data for Lead Asset 4MT2001 Demonstrating Central Nervous System Target Engagement

September 09, 2024

From 4M Therapeutics Inc.

Via Business Wire

4M Therapeutics Presented Novel Preclinical Data at SOBP Annual Meeting 2024 Demonstrating Potent Effects of Inhibitors of GSK3β for the Treatment of Bipolar Disorder

May 13, 2024

From 4M Therapeutics Inc.

Via Business Wire

4M Therapeutics Announces Formation of Clinical Advisory Board with Experts in Neuropsychiatry and Neurodegeneration

May 02, 2024

From 4M Therapeutics Inc.

Via Business Wire

4M Therapeutics Strengthens Executive Leadership Team with Appointment of Kimberly Lee, D.O. as Chief Business Officer

March 04, 2024

From 4M Therapeutics Inc.

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.